Our Team | Advisory Board

ACTI’s Advisory Board

Dr Brendan Shaw

Brendan is a former CEO of Medicines Australia. Over the last 10 years, he has managed many key medicines industry issues in Australia (e.g. the Pharmaceutical Benefits Scheme; IP policy, and the increasing internationalisation of Australian medicines). He was also the Board Director for Research Australia, one of the leading not-for-profit organisations commercialising early stage research.

Prof. David Anderson

David is the Deputy Director at the Burnet Institute. He has been responsible for overall coordination of R&D commercialisation; review and management of IP and new commercial opportunities. In 2013, he established the Burnet spinout Nanjing BioPoint Diagnostic Technology Ltd, as CEO. Nanjing BioPoint raised USD2.5m investment from Chinese PE in 2014, and established ISO13485-certified manufacturing facilities in China.

Russell Bateman

Russell is the COO of CPIC Allianz Health. He has had significant success commercialising Australian insurance and healthcare start-ups and held roles such as the Director of Operations of the Royal Melbourne Hospital, CEO of Latrobe University Private Hospital etc. and has considerable knowledge across healthcare and medical sectors across Australia, US and throughout Asia.

Shane Lawrence

Shane is the joint Managing Director of Questra Limited. He is an experienced company director with 15 years in private equity along with 13 years in the corporate world, SME management roles and running his own business. Shane co-founded and directed Blue Sky Partners, an SME consulting intermediary providing business strategy and capital raising services for the venture and start-up sector. In this role, Shane personally raised over $7M for clients, secured two trade sales, one acquisition and negotiated an international distribution rights agreement.

Location

49 Agnes Street 
East Melbourne
VIC 3002

 

Contact Us

0411 679 888

melvin@acti.asia

 

Follow Us